Core Insights - Sutro Biopharma, Inc. is hosting a virtual Research & Development Day on November 12, 2025, to showcase its platform innovation and next-generation antibody-drug conjugate (ADC) pipeline [1] Company Overview - Sutro Biopharma is focused on advancing a next-generation ADC platform that aims to deliver single- and dual-payload ADCs for cancer treatment [3] - The company's cell-free platform optimizes the antibody, linker, and payload to enhance drug exposure, minimize side effects, and broaden the range of treatable tumor types [3] - Sutro's unique capabilities in dual-payload ADCs are designed to address treatment resistance and expand therapeutic possibilities in oncology [3] - The pipeline targets large oncology markets that currently have limited treatment options and a significant need for improved therapies [3]